Predicting Survival in Patients with Pancreatic Cancer by Integrating Bone Marrow FDG Uptake and Radiomic Features of Primary Tumor in PET/CT

• Published in: Cancers Vol. 13; no. 14; p. 3563
• Main Authors: Lee, Jeong Won, Park, Sang-Heum, Ahn, Hyein, Lee, Sang Mi, Jang, Su Jin
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 16-07-2021; MDPI
• Subjects: Blood tests; Bone cancer; Bone marrow; Clinical outcomes; Computed tomography; Entropy; Glycolysis; Inflammation; Lesions; Liver; Medical imaging; Medical prognosis; Metabolism; Metastasis; Neutrophils; Pancreatic cancer; Patients; Radiomics; Survival analysis; Tomography; Tumors; Vertebrae
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13143563

The purpose of this study was to evaluate the prognostic significance of FDG uptake of bone marrow (BM SUV) and to investigate its role combined with radiomic features of primary tumors in improving the prediction of overall survival (OS) in patients with pancreatic cancer. We retrospectively enrolled 65 pancreatic cancer patients with staging FDG PET/CT. BM SUV and conventional imaging parameters of primary tumors including total lesion glycolysis (TLG) were measured. First-order and higher-order textural features of primary cancer were extracted using PET textural analysis. Associations of PET/CT parameters of bone marrow (BM) and primary cancer with OS were assessed. BM SUV as well as TLG and first-order entropy of pancreatic cancer were significant independent predictors of OS in multivariable analysis. A PET/CT scoring system based on the cumulative scores of these three independent predictors enabled patient stratification into three distinct prognostic groups. The scoring system yielded a good prognostic stratification based on subgroup analysis irrespective of tumor stage and treatment modality. BM SUV was an independent predictor of OS in pancreatic cancer patients. The PET/CT scoring system that integrated PET/CT parameters of primary tumors and BM can provide prognostic information in pancreatic cancer independent of tumor stage and treatment.